B6H12.2 is a commercially available anti-CD47 monoclonal antibody that efficiently blocks the interaction between CD47 and SIRPα in Laryngeal Squamous Cell Carcinoma (LSCC) in vitro. The gene discussed is CD47; the disease is laryngeal squamous cell carcinoma.